Development Platform Construction and Application Promotion of Drug-Eluting Stents for Intracranial Aneurysm Interventional Therapy

This study is a post-marketing clinical study of the Lattice Flow-Diverting Dense-Mesh Stent. It plans to enroll 280 patients, who will be treated for unruptured intracranial aneurysms using the Lattice Flow-Diverting Dense-Mesh Stent. Patients will be followed up at 12 months after device implantation, and data including the Raymond classification of the target aneurysms, the occurrence of complications, and whether complications result in neurological deficit symptoms will be collected and assessed. Through the above indicators, the clinical safety and efficacy of the product will be evaluated.

NCT Number	NCT07190781
Lead Sponsor	Xinjian Yang Collaborators: Xuanwu Hospital, Beijing, Beijing Chao Yang Hospital, Peking University International Hospital, Chinese PLA General Hospital
Conditions	Cerebral Aneurysm Unruptured
Enrollment	280 participants
Start Date	2022-10-24
Primary Completion	2022-10-24 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-24